BioRestorative Therapies, Inc. (NASDAQ:BRTX) Short Interest Update

BioRestorative Therapies, Inc. (NASDAQ:BRTX) was the target of a significant growth in short interest in the month of September. As of September 15th, there was short interest totalling 58,400 shares, a growth of 13.4% from the August 31st total of 51,500 shares. Based on an average daily volume of 56,300 shares, the short-interest ratio is currently 1.0 days. Currently, 1.2% of the shares of the company are sold short.

Institutional Investors Weigh In On BioRestorative Therapies

A hedge fund recently bought a new stake in BioRestorative Therapies stock. StoneX Group Inc. bought a new stake in BioRestorative Therapies, Inc. (NASDAQ:BRTX) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 34,850 shares of the company’s stock, valued at approximately $48,000. StoneX Group Inc. owned 0.51% of BioRestorative Therapies as of its most recent SEC filing. 69.38% of the stock is currently owned by hedge funds and other institutional investors.

BioRestorative Therapies Price Performance

BRTX stock traded up $0.04 during trading on Friday, hitting $1.74. 15,839 shares of the company traded hands, compared to its average volume of 904,026. BioRestorative Therapies has a 1 year low of $1.03 and a 1 year high of $3.67. The company has a market cap of $11.78 million, a PE ratio of -0.75 and a beta of 63.07. The stock’s 50-day simple moving average is $1.60 and its 200 day simple moving average is $1.53.

BioRestorative Therapies (NASDAQ:BRTX) last posted its earnings results on Tuesday, August 13th. The company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.06. The firm had revenue of $0.09 million during the quarter, compared to analysts’ expectations of $0.03 million. BioRestorative Therapies had a negative net margin of 6,898.28% and a negative return on equity of 107.65%. During the same period in the previous year, the business posted ($0.77) EPS. Research analysts expect that BioRestorative Therapies will post -1.83 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Roth Mkm lifted their price objective on shares of BioRestorative Therapies from $15.00 to $18.00 and gave the company a “buy” rating in a research note on Wednesday, August 14th.

About BioRestorative Therapies

BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.